ADC Therapeutics Q3 net product revenue $15.8M; net loss narrows to $41M; $60M PIPE strengthens cash

ADC Therapeutics SA

2025-Q3 EPS reported -$1.14 revenue$58,299,000

Q3 net product revenue $15.8M (down 12% YoY); nine-month 2025 revenue $51.2M vs $52.9M in 2024.
Net loss $41.0M ($0.30 per share) vs $44.0M ($0.42) in Q3 2024; adjusted net loss $25.5M ($0.19).
Completed $60M PIPE financing with $57.6M net proceeds; pro forma cash $292.3M to support ZYNLONTA expansion.
LOTIS-7 updated data by end of 2025; LOTIS-5 topline data expected 1H 2026; FL IIT shows ORR 98.2%, CR 83.6%.
IND-enabling for PSMA-targeting ADC to be completed by end of 2025; restructuring costs $13.5M YTD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.